Literature DB >> 23949206

Abuse-related and abuse-limiting effects of methcathinone and the synthetic "bath salts" cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats.

J S Bonano1, R A Glennon, L J De Felice, M L Banks, S S Negus.   

Abstract

RATIONALE: Abuse of synthetic cathinones, popularized as "bath salts," has increased dramatically in the USA since their debut in 2010. Preclinical behavioral studies may clarify determinants of the abuse-related effects produced by these compounds.
OBJECTIVES: This study examined behavioral effects of (±)-methcathinone, (±)-3,4-methylenedioxypyrovalerone (MDPV), (±)-3,4-methylenedioxymethcathinone (methylone), and (±)-4-methylmethcathinone (mephedrone) in rats using intracranial self-stimulation (ICSS).
METHODS: Male Sprague-Dawley rats (n = 18) with electrodes targeting the medial forebrain bundle responded for multiple frequencies of brain stimulation and were tested in two phases. First, dose-effect curves for methcathinone (0.1-1.0 mg/kg), MDPV (0.32-3.2 mg/kg), methylone (1.0-10 mg/kg), and mephedrone (1.0-10 mg/kg) were determined. Second, time courses were determined for effects produced by the highest dose of each compound.
RESULTS: Methcathinone produced dose- and time-dependent facilitation of ICSS. MDPV, methylone, and mephedrone produced dose- and time-dependent increases in low rates of ICSS maintained by low brain stimulation frequencies, but also produced abuse-limiting depression of high ICSS rates maintained by high brain stimulation frequencies. Efficacies to facilitate ICSS were methcathinoneMDPVmethylone > mephedrone. Methcathinone was the most potent compound, and MDPV was the longest acting compound.
CONCLUSIONS: All compounds facilitated ICSS at some doses and pretreatment times, which is consistent with abuse liability for each of these compounds. However, efficacies of compounds to facilitate ICSS varied, with methcathinone displaying the highest efficacy and mephedrone displaying the lowest efficacy to facilitate ICSS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23949206      PMCID: PMC3877726          DOI: 10.1007/s00213-013-3223-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  37 in total

1.  The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue.

Authors:  Michael H Baumann; Mario A Ayestas; John S Partilla; Jacqueline R Sink; Alexander T Shulgin; Paul F Daley; Simon D Brandt; Richard B Rothman; Arnold E Ruoho; Nicholas V Cozzi
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

2.  Mephedrone (4-methylmethcathinone) and intracranial self-stimulation in C57BL/6J mice: comparison to cocaine.

Authors:  J Elliott Robinson; Abigail E Agoglia; Eric W Fish; Michael C Krouse; C J Malanga
Journal:  Behav Brain Res       Date:  2012-06-21       Impact factor: 3.332

Review 3.  Drugs for youth via Internet and the example of mephedrone.

Authors:  I Vardakou; C Pistos; Ch Spiliopoulou
Journal:  Toxicol Lett       Date:  2010-12-25       Impact factor: 4.372

4.  4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse.

Authors:  Gregory C Hadlock; Katy M Webb; Lisa M McFadden; Pei Wen Chu; Jonathan D Ellis; Scott C Allen; David M Andrenyak; Paula L Vieira-Brock; Christopher L German; Kevin M Conrad; Amanda J Hoonakker; James W Gibb; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2011-08-02       Impact factor: 4.030

5.  Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply.

Authors:  Karen McElrath; Christina O'Neill
Journal:  Int J Drug Policy       Date:  2011-01-15

6.  Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States.

Authors:  Henry A Spiller; Mark L Ryan; Robert G Weston; Joanne Jansen
Journal:  Clin Toxicol (Phila)       Date:  2011-07       Impact factor: 4.467

7.  Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone.

Authors:  Raul López-Arnau; Jose Martínez-Clemente; David Pubill; Elena Escubedo; Jorge Camarasa
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

8.  Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines.

Authors:  N V Cozzi; M K Sievert; A T Shulgin; P Jacob; A E Ruoho
Journal:  Eur J Pharmacol       Date:  1999-09-17       Impact factor: 4.432

9.  Illicit bath salts: not for bathing.

Authors:  Patrick B Kyle; Richard B Iverson; Raghavendran G Gajagowni; Lee Spencer
Journal:  J Miss State Med Assoc       Date:  2011-12

10.  Discriminative stimulus effects of S(-)-methcathinone (CAT): a potent stimulant drug of abuse.

Authors:  R Young; R A Glennon
Journal:  Psychopharmacology (Berl)       Date:  1998-12       Impact factor: 4.530

View more
  73 in total

1.  Intravenous self-administration of entactogen-class stimulants in male rats.

Authors:  Sophia A Vandewater; Kevin M Creehan; Michael A Taffe
Journal:  Neuropharmacology       Date:  2015-08-21       Impact factor: 5.250

2.  Mephedrone alters basal ganglia and limbic dynorphin systems.

Authors:  Christopher L German; Mario E Alburges; Amanda J Hoonakker; Annette E Fleckenstein; Glen R Hanson
Journal:  Synapse       Date:  2014-09-08       Impact factor: 2.562

3.  Reinforcing and neurochemical effects of the "bath salts" constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats.

Authors:  Charles W Schindler; Eric B Thorndike; Steven R Goldberg; Kurt R Lehner; Nicholas V Cozzi; Simon D Brandt; Michael H Baumann
Journal:  Psychopharmacology (Berl)       Date:  2015-08-29       Impact factor: 4.530

Review 4.  Synthetic cathinones: chemical phylogeny, physiology, and neuropharmacology.

Authors:  Louis J De Felice; Richard A Glennon; Sidney S Negus
Journal:  Life Sci       Date:  2013-11-11       Impact factor: 5.037

5.  Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.

Authors:  Farhana Sakloth; Elizabeth Leggett; Megan J Moerke; E Andrew Townsend; Matthew L Banks; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2019-01-10       Impact factor: 3.157

6.  Amphetamine maintenance differentially modulates effects of cocaine, methylenedioxypyrovalerone (MDPV), and methamphetamine on intracranial self-stimulation and nucleus accumbens dopamine in rats.

Authors:  Amy R Johnson; Matthew L Banks; Dana E Selley; S Stevens Negus
Journal:  Neuropsychopharmacology       Date:  2018-04-19       Impact factor: 7.853

7.  Locomotor Stimulant and Rewarding Effects of Inhaling Methamphetamine, MDPV, and Mephedrone via Electronic Cigarette-Type Technology.

Authors:  Jacques D Nguyen; Shawn M Aarde; Maury Cole; Sophia A Vandewater; Yanabel Grant; Michael A Taffe
Journal:  Neuropsychopharmacology       Date:  2016-06-09       Impact factor: 7.853

8.  Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats.

Authors:  Todd M Hillhouse; Joseph H Porter; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

9.  Stereochemistry and neuropharmacology of a 'bath salt' cathinone: S-enantiomer of mephedrone reduces cocaine-induced reward and withdrawal in invertebrates.

Authors:  Alexandre Vouga; Ryan A Gregg; Maryah Haidery; Anita Ramnath; Hassan K Al-Hassani; Christopher S Tallarida; David Grizzanti; Robert B Raffa; Garry R Smith; Allen B Reitz; Scott M Rawls
Journal:  Neuropharmacology       Date:  2014-12-09       Impact factor: 5.250

10.  Effects of 3,4-methylenedioxypyrovalerone (MDPV) pre-exposure on the aversive effects of MDPV, cocaine and lithium chloride: Implications for abuse vulnerability.

Authors:  Claudia J Woloshchuk; Katharine H Nelson; Kenner C Rice; Anthony L Riley
Journal:  Drug Alcohol Depend       Date:  2016-08-07       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.